DCCR ‘Worked Across the Board’ in PWS Trial, But Results Are Less Clear

DCCR ‘Worked Across the Board’ in PWS Trial, But Results Are Less Clear

295717

DCCR ‘Worked Across the Board’ in PWS Trial, But Results Are Less Clear

Editor’s Note: This is the second of two articles looking at DCCR, Soleno Therapeutics’ investigational treatment, and the DESTINY-PWS trial. The first can be found here.  Likely next steps for diazoxide choline controlled release (DCCR) tablets, a potential therapy for Prader-Willi syndrome (PWS), remain to be known, as discussions continue between Soleno Therapeutics, the treatment’s developer, and the U.S. Food and Drug Administration (FDA). At issue is how heavily the global COVID-19 pandemic weighted on outcomes of…

You must be logged in to read/download the full post.